| 06/09/23 | 07:00:06 | 6 Sept 2023 | | Update on US review of Ultomiris for NMOSD |
| 01/09/23 | 15:00:01 | 1 Sept 2023 | | Total Voting Rights |
| 01/08/23 | 15:00:01 | 1 Aug 2023 | | Total Voting Rights |
| 28/07/23 | 07:05:01 | 28 Jul 2023 | | Alexion enters gene therapy agreement with Pfizer |
| 28/07/23 | 07:00:06 | 28 Jul 2023 | | Half-year Report |
| 17/07/23 | 18:10:56 | 17 Jul 2023 | | Beyfortus approved in US for infant RSV prevention |
| 03/07/23 | 15:00:01 | 3 Jul 2023 | | Total Voting Rights |
| 03/07/23 | 07:00:06 | 3 Jul 2023 | | Dato-DXd significantly improved PFS in lung cancer |
| 09/06/23 | 07:05:01 | 9 Jun 2023 | | nirsevimab recommended for infant RSV protection |
| 09/06/23 | 07:00:05 | 9 Jun 2023 | | AstraZeneca agreement with Quell Therapeutics |
| 02/06/23 | 17:00:01 | 2 Jun 2023 | | Imfinzi improved pCR in gastric and GEJ cancers |
| 01/06/23 | 15:05:01 | 1 Jun 2023 | | Block listing Interim Review |
| 01/06/23 | 15:00:03 | 1 Jun 2023 | | Total Voting Rights |
| 01/06/23 | 07:00:10 | 1 Jun 2023 | | Lynparza approved in US for BRCAm prostate cancer |
| 26/05/23 | 07:00:05 | 26 May 2023 | | Imfinzi + Lynparza prolonged PFS in endometrial ca |
| 22/05/23 | 07:05:01 | 22 May 2023 | | Directorate Change |
| 17/05/23 | 07:00:07 | 17 May 2023 | | Tagrisso plus chemo improved PFS in lung cancer |
| 09/05/23 | 11:00:09 | 9 May 2023 | | Director/PDMR Shareholding |
| 09/05/23 | 07:00:16 | 9 May 2023 | | Farxiga extended in the US for heart failure |
| 02/05/23 | 15:00:01 | 2 May 2023 | | Total Voting Rights |
| 02/05/23 | 10:00:02 | 2 May 2023 | | Director/PDMR Shareholding |
| 02/05/23 | 07:00:12 | 2 May 2023 | | ODAC vote on Lynparza combo in prostate cancer |
| 27/04/23 | 17:30:01 | 27 Apr 2023 | | Result of AGM |
| 27/04/23 | 07:05:01 | 27 Apr 2023 | | Board Committee Changes |
| 27/04/23 | 07:00:05 | 27 Apr 2023 | | 1st Quarter Results |
| 26/04/23 | 16:45:01 | 26 Apr 2023 | | Director Declaration |
| 11/04/23 | 07:00:08 | 11 Apr 2023 | | Update to arrangements with Sobi and Sanofi |
| 05/04/23 | 07:00:04 | 5 Apr 2023 | | Lynparza + Imfinzi met endpoint in ovarian cancer |
| 03/04/23 | 15:00:01 | 3 Apr 2023 | | Total Voting Rights |
| 03/04/23 | 07:00:11 | 3 Apr 2023 | | Ultomiris recommended for NMOSD EU approval |
| 30/03/23 | 07:00:03 | 30 Mar 2023 | | AstraZeneca completes KYM agreement for CMG901 |
| 27/03/23 | 11:00:01 | 27 Mar 2023 | | Director/PDMR Shareholding |
| 22/03/23 | 11:00:02 | 22 Mar 2023 | | Notice of AGM |
| 09/03/23 | 07:00:06 | 9 Mar 2023 | | Imfinzi improved EFS in resectable lung cancer |
| 08/03/23 | 11:01:01 | 8 Mar 2023 | | Director/PDMR Shareholding |
| 08/03/23 | 11:00:01 | 8 Mar 2023 | | Director/PDMR Shareholding |
| 06/03/23 | 07:00:04 | 6 Mar 2023 | | Enhertu DESTINY-PanTumor02 shows positive results |
| 01/03/23 | 15:00:01 | 1 Mar 2023 | | Total Voting Rights |
| 01/03/23 | 07:00:10 | 1 Mar 2023 | | AstraZeneca prices a $2.25bn bond offering |
| 24/02/23 | 18:15:00 | 24 Feb 2023 | | AstraZeneca prices a EUR1.5bn bond offering |
| 24/02/23 | 14:05:01 | 24 Feb 2023 | | AstraZeneca acquires CinCor for cardiorenal asset |
| 24/02/23 | 11:00:01 | 24 Feb 2023 | | Director/PDMR Shareholding |
| 23/02/23 | 07:00:08 | 23 Feb 2023 | | AstraZeneca enters agreement with KYM for CMG901 |
| 22/02/23 | 07:10:02 | 22 Feb 2023 | | Filing of Form 20-F with SEC |
| 21/02/23 | 11:00:01 | 21 Feb 2023 | | Annual Financial Report |
| 13/02/23 | 14:01:01 | 13 Feb 2023 | | Director/PDMR Shareholding |
| 13/02/23 | 14:00:01 | 13 Feb 2023 | | Director/PDMR Shareholding |
| 09/02/23 | 07:00:08 | 9 Feb 2023 | | Final Results |
| 01/02/23 | 15:00:00 | 1 Feb 2023 | | Total Voting Rights |
| 26/01/23 | 18:15:00 | 26 Jan 2023 | | Update on Evusheld US EUA |
